IN2014DN07149A - - Google Patents

Info

Publication number
IN2014DN07149A
IN2014DN07149A IN7149DEN2014A IN2014DN07149A IN 2014DN07149 A IN2014DN07149 A IN 2014DN07149A IN 7149DEN2014 A IN7149DEN2014 A IN 7149DEN2014A IN 2014DN07149 A IN2014DN07149 A IN 2014DN07149A
Authority
IN
India
Prior art keywords
antibodies
diagnosis
treatment
present application
application discloses
Prior art date
Application number
Other languages
English (en)
Inventor
Jose Saldanha
Tarlochan S Nijjar
Original Assignee
Neotope Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neotope Biosciences Ltd filed Critical Neotope Biosciences Ltd
Publication of IN2014DN07149A publication Critical patent/IN2014DN07149A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
IN7149DEN2014 2012-01-27 2013-01-25 IN2014DN07149A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261591835P 2012-01-27 2012-01-27
US201261711207P 2012-10-08 2012-10-08
PCT/US2013/023307 WO2013112945A1 (en) 2012-01-27 2013-01-25 Humanized antibodies that recognize alpha-synuclein

Publications (1)

Publication Number Publication Date
IN2014DN07149A true IN2014DN07149A (zh) 2015-04-24

Family

ID=48873980

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7149DEN2014 IN2014DN07149A (zh) 2012-01-27 2013-01-25

Country Status (23)

Country Link
US (7) US8790644B2 (zh)
EP (1) EP2807188B1 (zh)
JP (2) JP6342333B2 (zh)
KR (2) KR102086061B1 (zh)
CN (2) CN104619724B (zh)
AU (1) AU2013211874B2 (zh)
BR (1) BR112014018561A8 (zh)
CA (1) CA2863953A1 (zh)
CL (1) CL2014001984A1 (zh)
DK (1) DK2807188T3 (zh)
ES (1) ES2749457T3 (zh)
HK (1) HK1204791A1 (zh)
IL (2) IL233829B (zh)
IN (1) IN2014DN07149A (zh)
MX (2) MX360778B (zh)
MY (1) MY171140A (zh)
NZ (1) NZ629296A (zh)
PH (1) PH12014501685A1 (zh)
RU (1) RU2642262C2 (zh)
SG (1) SG11201404321YA (zh)
UA (1) UA115439C2 (zh)
WO (1) WO2013112945A1 (zh)
ZA (1) ZA201406227B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63930B1 (sr) 2011-10-28 2023-02-28 Prothena Biosciences Ltd Humanizovana antitela koja prepoznaju alfa-sinuklein
KR102086061B1 (ko) * 2012-01-27 2020-03-11 프로테나 바이오사이언시즈 리미티드 알파-시누클레인을 인식하는 인간화된 항체
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
EP3016681B1 (en) * 2013-07-05 2019-12-18 Genmab A/S Humanized or chimeric cd3 antibodies
EP3071597B1 (en) * 2013-11-21 2020-07-29 F.Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US9732148B2 (en) 2014-10-16 2017-08-15 Genentech, Inc. Anti-α-synuclein antibodies and methods of use
CN106568969B (zh) * 2016-10-19 2017-09-26 首都医科大学 一种丝氨酸129位磷酸化alpha‑突触核蛋白聚集体的ELISA检测方法
CA3042302A1 (en) 2016-12-02 2018-06-07 Prothena Biosciences Limited Infrared assay detecting secondary structure profiles of alpha-synuclein
JP7136790B2 (ja) * 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
EP3406632A1 (en) 2017-05-23 2018-11-28 S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati Ligands binding to prion protein for use in the treatment of synucleinopathies
CA3085572A1 (en) * 2017-12-14 2019-06-20 Abl Bio Inc. Bispecific antibody to a-syn/igf1r and use thereof
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
CN113226367A (zh) 2018-04-06 2021-08-06 Atyr 医药公司 包括抗nrp2抗体的组合物和方法
CA3108986A1 (en) 2018-08-09 2020-02-13 Ventana Medical Systems, Inc. Determination of parkinson's disease
US20210347868A1 (en) * 2018-10-19 2021-11-11 Gabriel Pascual Anti-synuclein antibodies
JP2022551603A (ja) * 2019-10-03 2022-12-12 エータイアー ファーマ， インコーポレイテッド 抗ｎｒｐ２抗体を含む組成物および方法
CR20220531A (es) 2020-04-24 2022-11-28 Hoffmann La Roche Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados
AU2021310926A1 (en) * 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies
CN113912714B (zh) * 2021-12-15 2022-02-22 北京凯祥弘康生物科技有限公司 特异性结合α-突触核蛋白的抗体及其应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE69620877T2 (de) 1995-02-06 2002-12-12 Genetics Inst Arzneimittelformulierungen für il-12
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
WO2000046750A1 (en) 1999-02-05 2000-08-10 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
EP1531864A4 (en) * 2002-05-13 2006-08-23 Alexion Pharma Inc HUMANIZED ANTIBODIES TO THE VENEZOLAN HORSEMEN ENZEPHALITIS VIRUS
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
WO2008103472A2 (en) * 2007-02-23 2008-08-28 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
KR101149777B1 (ko) 2002-11-29 2012-06-11 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 신규한 네오마이신 포스포트랜스퍼라제 유전자 및 고생산성 재조합 세포의 선별 방법
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
EP1697741A4 (en) 2003-12-04 2008-02-13 Xencor Inc PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE602005014805D1 (de) 2004-11-10 2009-07-16 Boehringer Ingelheim Pharma Verwendung von durchflusszytometrischer analyse zur optimierung von zellbankingstrategien für cho-zellen
US7930064B2 (en) * 2004-11-19 2011-04-19 Parata Systems, Llc Automated drug discrimination during dispensing
WO2007011907A2 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
AU2007275467B2 (en) 2006-07-14 2013-12-05 Ac Immune S.A. Humanized antibody against amyloid beta
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
ES2635317T3 (es) * 2007-01-05 2017-10-03 University Of Zurich Anticuerpo anti-beta-amiloide y sus usos
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
US8221999B2 (en) 2007-03-02 2012-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Protein production
UA96473C2 (ru) 2007-03-22 2011-11-10 Имклоун Ллк Жидкая стойкая композиция, которая содержит антитело imc-а12
CA2681341A1 (en) 2007-03-22 2008-09-25 Genentech, Inc. Apoptotic anti-ige antibodies
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
UA101487C2 (en) 2007-12-21 2013-04-10 Ф. Хоффманн-Ля Рош Аг Humanized b-ly1 antibody formulation
EA028356B1 (ru) 2007-12-28 2017-11-30 Протена Байосайенсиз Лимитед Лечение и профилактика амилоидоза
AT506535B1 (de) * 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
DK2282758T3 (en) 2008-04-29 2019-02-25 Bioarctic Ab ANTIBODIES AND VACCINES FOR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR ALPHA-SYNUCLEIN-RELATED DISORDERS
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US20120276019A1 (en) 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
DE102008048129A1 (de) 2008-09-20 2010-04-22 Lfk-Lenkflugkörpersysteme Gmbh Flugkörper mit zumindest einem Bremsfallschirm sowie Befestigungsvorrichtung zur Befestigung eines Bremsfallschirms an einem Flugkörper
JP5810413B2 (ja) 2008-12-19 2015-11-11 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗アルファシヌクレイン自己抗体
MX344786B (es) 2009-07-28 2017-01-06 Shire Human Genetic Therapies Composiciones y metodos para tratar enfermedad de gaucher.
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011090720A2 (en) 2009-12-29 2011-07-28 Dr. Reddy's Laboratories Ltd Purification of proteins
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CA2795279C (en) * 2010-04-08 2020-05-05 Jn Biosciences Llc Antibodies to cd122
WO2011156328A1 (en) * 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN103079644B (zh) * 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
NO2593128T3 (zh) * 2010-07-15 2018-06-09
BR112013008738B1 (pt) 2010-10-11 2017-12-19 Abbvie Bahamas Ltd. Method for purification of a protein
US20140050733A1 (en) 2011-02-07 2014-02-20 Dale B. Schenk Apoe immunotherapy
WO2012160536A1 (en) 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
WO2012177997A1 (en) 2011-06-22 2012-12-27 The General Hospital Corporation Treatment of proteinopathies
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
RS63930B1 (sr) 2011-10-28 2023-02-28 Prothena Biosciences Ltd Humanizovana antitela koja prepoznaju alfa-sinuklein
EP3091029B1 (en) 2011-10-31 2022-12-28 F. Hoffmann-La Roche AG Anti-il13 antibody formulations
KR102086061B1 (ko) 2012-01-27 2020-03-11 프로테나 바이오사이언시즈 리미티드 알파-시누클레인을 인식하는 인간화된 항체
KR101885044B1 (ko) 2012-08-29 2018-08-02 에프. 호프만-라 로슈 아게 혈액 뇌 장벽 셔틀
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US10084674B2 (en) 2015-09-09 2018-09-25 International Business Machines Corporation Virtual desktop operation and data continuity preservation

Also Published As

Publication number Publication date
DK2807188T3 (da) 2019-10-07
JP2015508062A (ja) 2015-03-16
BR112014018561A2 (zh) 2017-06-20
US20190153080A1 (en) 2019-05-23
IL281731A (en) 2021-05-31
CN104619724B (zh) 2018-05-04
IL233829A0 (en) 2014-09-30
IL233829B (en) 2021-04-29
EP2807188B1 (en) 2019-09-11
MX2018014044A (es) 2021-12-08
US9234031B2 (en) 2016-01-12
UA115439C2 (uk) 2017-11-10
WO2013112945A1 (en) 2013-08-01
MX360778B (es) 2018-11-16
US20200277362A1 (en) 2020-09-03
US9670273B2 (en) 2017-06-06
JP6342333B2 (ja) 2018-06-13
PH12014501685A1 (en) 2014-11-10
JP2018148911A (ja) 2018-09-27
CA2863953A1 (en) 2013-08-01
KR20140125409A (ko) 2014-10-28
JP6807893B2 (ja) 2021-01-06
MX2014008952A (es) 2015-02-20
RU2014134747A (ru) 2016-03-20
ES2749457T3 (es) 2020-03-20
CL2014001984A1 (es) 2014-12-19
HK1204791A1 (zh) 2015-12-04
AU2013211874B2 (en) 2017-11-02
NZ629296A (en) 2016-06-24
BR112014018561A8 (pt) 2017-07-11
US20130266517A1 (en) 2013-10-10
US20160251416A1 (en) 2016-09-01
KR102246217B1 (ko) 2021-04-29
AU2013211874A1 (en) 2014-09-18
US20150024433A1 (en) 2015-01-22
MY171140A (en) 2019-09-27
KR102086061B1 (ko) 2020-03-11
SG11201404321YA (en) 2014-08-28
CN104619724A (zh) 2015-05-13
US9217030B2 (en) 2015-12-22
US10118960B2 (en) 2018-11-06
KR20200027570A (ko) 2020-03-12
CN108517010A (zh) 2018-09-11
US8790644B2 (en) 2014-07-29
US10875909B2 (en) 2020-12-29
EP2807188A4 (en) 2015-07-01
US20180016329A1 (en) 2018-01-18
US20150056187A1 (en) 2015-02-26
US10597441B2 (en) 2020-03-24
RU2642262C2 (ru) 2018-01-24
ZA201406227B (en) 2016-02-24
EP2807188A1 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
IN2014DN07149A (zh)
MX2019014658A (es) Anticuerpos humanizados que reconocen la alfa-sinucleina.
GEP20217263B (en) Anti-cd27 antibodies
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
EA201591198A1 (ru) Антитела к gdf15
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
EA201791186A1 (ru) Антитела к cd38
UA107827C2 (en) Antibody cd40
EA201491541A1 (ru) АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
EP2955195A4 (en) ANTI-SEMAPHORIN-3A ANTIBODY AND TREATMENT OF ALZHEIMER AND INFLAMMATORY IMMUNE DISEASES THEREWITH
EP3010938A4 (en) Fcrn-specific human antibody and composition for treatment of autoimmune diseases
MX359794B (es) Anticuerpos anti-hepcidina y usos de los mismos.
HK1258028A1 (zh) 人類抗體及其在神經疾病治療中的診斷和治療用途
EP2694530A4 (en) NOVEL PEPTIDES THAT BIND TYPES OF CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX AND THEIR USE FOR DIAGNOSIS AND TREATMENT
EP2700652A4 (en) DIAGNOSIS AND TREATMENT OF CANCER BY ANTI-ITM2A ANTIBODIES
EP3628326C0 (en) METHODS AND SUBSTANCES FOR TREATING PUMP DISEASE
GB201109238D0 (en) Antibodies
HK1201045A1 (zh) 用於腫瘤診斷和治療的組合物和方法
EP2563395A4 (en) TREATMENT WITH ANTI-S1P ANTIBODY OF PATIENTS WITH OCULAR DISEASES
FR2979346B1 (fr) Nanocorps anti-vcam-1
EP2569334A4 (en) RECOMBINANT-PRODUCED ANTIBODIES FOR THE TARGETING OF ERBB SIGNALING MOLECULES AND METHOD FOR THEIR USE FOR DISEASE DIAGNOSIS AND TREATMENT
IL284807A (en) Antibodies specific for human nectin-2
HK1216903A1 (zh) 抗體-尿素酶偶聯物在診斷和治療中的應用
MX2013009529A (es) Tratamiento de enfermedad de crohn con fistulas.
LT2984108T (lt) Anti-s100a7 antikūnai, skirti vėžio gydymui ir diagnozei